And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback